Tumor recurrence or regrowth in adults with nonfunctioning pituitary adenomas using GH replacement therapy
|
|
- Ethan Mathews
- 5 years ago
- Views:
Transcription
1 Tumor recurrence or regrowth in adults with nonfunctioning pituitary adenomas using GH replacement therapy N. C. van Varsseveld C. C. van Bunderen A. A. M. Franken H. P. F. Koppeschaar A. J. van der Lely M. L. Drent The Journal of Clinical Endocrinology & Metabolism 201; 100(8):
2 Abstract Context Growth hormone replacement therapy (GH-RT) is a widely accepted treatment in growth hormone deficient (GHD) adults with nonfunctioning pituitary adenomas (NFPAs). However, some concerns have been raised about the safety of GH-RT, because of its potentially stimulating effect on tumor growth. Objective The aim of this study was to evaluate tumor progression in NFPA patients using GH-RT. Design, Setting, and Patients From the Dutch National Registry of Growth Hormone Treatment in Adults, a nationwide surveillance study in severe GHD adults ( ), all NFPA patients with 30 days of GH-RT were selected (n = 783). Data were retrospectively collected from the start of GH-RT in adulthood (baseline). Main Outcome Measure Tumor progression, including tumor recurrence after complete remission at baseline and regrowth of residual tumor. Results Tumor progression developed in 12.1% of the patients after a median time of 2.2 ( ) years. Prior radiotherapy decreased tumor progression risk compared to no radiotherapy (hazard ratio [HR] = 0.16, 9% confidence interval [CI], ). Analysis in 77 patients with available baseline imaging data showed that residual tumor at baseline increased tumor progression risk compared to no residual tumor (HR = 4., 9% CI, ). Conclusions The findings in this large study were in line with those reported in literature and provide further evidence that GH-RT does not appear to increase tumor progression risk in NFPA patients. Although only long-term randomized controlled trials will be able to draw firm conclusions, our data support the current view that GH-RT is safe in NFPA patients. 90
3 Tumor progression in NFPA patients using GH-RT Introduction Clinically nonfunctioning pituitary adenomas (NFPAs) are relatively common benign tumors of the anterior pituitary gland 1. These tumors frequently present with symptoms and signs of tumor mass effects on adjacent structures due to the absence of features of pituitary hormone hypersecretion 2. The treatment of choice for NFPAs usually is transsphenoidal surgery. The main goals of surgery include complete removal or debulking of the tumor and relieve of tumor mass effects on surrounding structures. Pituitary radiotherapy is an additional treatment option, which may be considered for instance after incomplete surgical resection 3. After surgery alone, reported rates of tumor recurrence or enlargement range between 6% and 46% 2. After radiotherapy, recurrence rates of approximately 10% or less have been reported, indicating that adjuvant radiotherapy may improve local tumor control 3-6. The treatment of a NFPA or the effects of the tumor itself often result in the development of hypopituitarism, including growth hormone deficiency (GHD) 2. The presence of GHD has been reported in up to 8% of NFPA patients 2,7. Adult GHD is, amongst others, associated with adverse changes in cardiovascular risk factors, body composition, bone mineral density, and quality of life 8. Because growth hormone replacement therapy (GH-RT) has shown beneficial effects on most of these features, many adult GHD patients are nowadays treated with GH-RT However, some concerns have been raised about the safety of GH-RT in patients with a NFPA, because of the possible stimulating effect of growth hormone (GH) on tumor recurrence or regrowth. Basic research indicates that GH and insulin-like growth factor 1 (IGF-1), through regulation of cell proliferation and apoptosis, may be involved in tumor development and growth 12,13. In addition, acromegaly, characterized by elevated GH and IGF-1 concentrations, has been associated with an increased risk of colonic neoplasia 14. Some epidemiological studies, although not all, suggest that even high-normal IGF-1 concentrations within the age- and gender-adjusted reference range may increase the risk of prostate, colorectal or breast cancer 1. Studies investigating tumor regrowth or recurrence in pituitary adenoma (PA) patients using GH-RT are relatively scarce in literature 11, Interpretation and comparison of these studies is difficult due to differences in defining tumor growth, follow-up times and study populations; for example, some studies included patients with various types of PAs. Despite these limitations, reported data so far seem to be reassuring with regard to effect of GH-RT on tumor regrowth or recurrence, but with the caveat that larger, long-term follow-up studies are needed 21,24. To date, essentially three studies have assessed the influence of GH-RT on tumor growth in NFPA patients specifically 17,19,20. 91
4 In these studies, tumor regrowth or recurrence did not seem to be affected by GH-RT. However, study population sizes were relatively small. The aim of the present study, therefore, was to evaluate tumor regrowth or recurrence in a large cohort of NFPA patients with GH-RT, using data from the Dutch National Registry of Growth Hormone Treatment in Adults, a nationwide long-term surveillance study in severe GHD adult patients. Subjects and methods Study population In 1998, the Dutch National Registry of Growth Hormone Treatment in Adults was initiated by the Dutch Ministry of Health to gain more insight into the long-term efficacy, safety and costs of GH-RT in GHD adults. From that time on, reimbursement of GH-RT costs was only granted after approval of the diagnosis of severe GHD by an independent board of endocrinologists as well as inclusion of anonymized patient data into the registry. All patients were informed by their attending physician. Severe GHD was diagnosed according to the Growth Hormone Research Society consensus guidelines 2. Data collection, patient characteristics, and test procedures have previously been described in more detail 26,27. Until data closure in 2009, 2891 severe GHD adults were registered. For the present study, all severely GHD patients with a (treated) NFPA (n = 893) were selected. Patients with < 30 days of GH-RT were excluded (n = 110). Compared to those included in the study (n = 783), excluded patients had a similar age at entry into the registry (p = 0.27), gender (p = 0.69), and onset of GHD (p = 1.00). Patients who were lost to follow-up, who died, or who stopped GH-RT were censored in the analyses. Tumor progression leading to discontinuation of GH-RT was included in the analyses. Measurements The data of all registered patients were collected (bi-) annually from medical records by specially trained monitors from the start of enrollment in the registry. When GH-RT had already been started before the first monitor visit, data were retrospectively retrieved. The anonymized collected data were checked for accuracy both before and after entry into the database. In 10% of the patients, data were collected twice by different monitors as an internal quality control. Persons-years of treatment with GH-RT were calculated from the date of commencement with GH-RT in adulthood (baseline) until the date of last follow-up, 92
5 Tumor progression in NFPA patients using GH-RT discontinuation of GH-RT, or death. The GH dose was titrated on an individual basis by the attending physician with the purpose of achieving and maintaining age- and gender-specific normalized IGF-1 SD scores. Changes in GH dosage were recorded, and the mean dose per patient was calculated as the cumulative dosage divided by the sum of GH-RT days. The diagnosis of NFPA, made at the discretion of the attending physician, was verified at entry into the database, according to the collected data. Data regarding the treatment of the NFPA, such as number, type and timing of surgical procedures and radiotherapy, were collected. Other pituitary hormone deficiencies in addition to GHD were identified through recorded deficiencies and hormonal replacement therapies, based on diagnostic tests performed by the attending physicians, at the start of registration and during follow-up. These deficiencies were adequately substituted when appropriate. Smoking status and alcohol use were also recorded from the start of entry into the registry. Data concerning relevant medical history, NFPA treatment, neuroradiological imaging and adverse events were searched and recorded thoroughly and coded for, amongst others, tumor progression. The definition of tumor progression included tumor recurrence in patients without detectable tumor at baseline as well as tumor regrowth in patients with detectable residual tumor at baseline, irrespective of the extent or clinical consequence of the tumor progression. The date of tumor progression was the date of the first recorded event. Cause and date of death were retrieved from medical records and death certificates from the Dutch Central Bureau of Statistics, as described previously 27. Statistical analysis Continuous variables were expressed as either mean (SD) or median (range), whereas categorical variables were expressed as number (percentage). The student s t-test was used to compare normally distributed continuous variables, whereas the Mann- Whitney test was used for skewed variables. Categorical variables were compared with the Chi-square or Fisher s exact test. Kaplan-Meier survival curves were used to describe the progression-free survival. Cox proportional hazard analysis was used to evaluate the risk of developing tumor progression in patients who had received prior radiotherapy compared with those who had not received prior radiotherapy and in patients with residual tumor at baseline compared with patients without residual tumor at baseline, respectively. In all analyses, time was measured from start of GH-RT in adulthood until the date of first tumor progression, last follow-up, or death, whichever occurred first. Assumptions of proportional hazards were tested by log-minus-log plots and interaction terms. To 93
6 adjust for the potentially confounding effects of age at baseline and gender, these variables were included in the Cox proportional hazard models. Other potentially confounding variables, including age at NFPA diagnosis, extension of pituitary deficiency (isolated GHD or multiple pituitary hormone deficiencies), pituitary surgery, radiotherapy and history of tumor progression were examined by adding them separately to the age- and gender-adjusted models. Variables that gave a change in the regression coefficient of > 10% were included in the model. All continuous variables were individually checked for linearity with the outcome variable and, in case of nonlinearity, divided in categories. Potential effect modification by gender was examined by adding an interaction term to the age- and gender-adjusted model. In case of a p-value < 0.10, analyses were stratified for gender. All statistical analyses were performed using the statistical software package IBM SPSS Statistics version 20 (SPSS Inc). Two-sided p-values of 0.0 were considered significant. Results Baseline characteristics Severe GHD was diagnosed with a GH stimulation test in 702 (89.7%) of the 783 patients included in the study (4.8% insulin tolerance test, 23.4% GH-releasing hormone [GHRH]/arginine test, 13.4% arginine test, 8.0% GHRH test, 0.4% other). In 7 (9.6%) patients, the diagnosis was based on IGF-1 concentrations 2 SD in combination with two or more additional pituitary hormone deficiencies. In the remaining cases, either retesting was considered unnecessary because of childhood onset GHD due to evident hypothalamic pituitary disease (n = 2 [0.3%]) or the diagnostic procedure was unknown (n = 4 [0.%]). Characteristics of the total study population and of patients with and without tumor progression during follow-up are shown in table 1. In operated patients, the surgical approach was transsphenoidal in 80 (79.9%) of the cases, transcranial in 118 (16.3%), and unknown in 28 (3.8%). Most irradiated patients (66.7%) were treated with conventional radiotherapy, whereas a minority (.9%) received stereotactic radiotherapy. In the remaining cases (30%), the method used was unknown. In 96 (76.1%) patients, baseline pituitary imaging data were available (table 2). Compared to those with baseline imaging data, patients without baseline imaging data had a similar age at baseline (p = 0.22), gender (p = 0.84), occurrence of tumor progression (p = 0.14) and duration of GH-RT (p = 0.10). 94
7 Tumor progression in NFPA patients using GH-RT Table 1 Baseline characteristics of all patients and of patients with and without tumor progression All patients No tumor progression Tumor progression P-value a No. of patients Age at baseline, years (mean, SD) 4.8 (11.6).1 (11.7) 2.8 (10.6) 0.07 Age at NFPA diagnosis, years (mean, SD) 48.0 (13.2) 47.8 (13.) 49.2 (11.0) 0.33 Gender 0.26 Males 478 (61.0) 41 (60.3) 63 (66.3) Females 30 (39.0) 273 (39.7) 32 (33.7) Extension of pituitary insufficiency, IGHD 40 (.1) 34 (4.9) 6 (6.3) 0.62 ACTH insufficiency 601 (76.8) 30 (77.0) 71 (74.7) 0.62 TSH insufficiency 627 (80.1) 1 (80.1) 76 (80.0) 0.98 LH/FSH insufficiency 636 (81.2) 60 (81.4) 76 (80.0) 0.74 ADH insufficiency 10 (13.4) 91 (13.2) 14 (14.7) 0.69 PRL insufficiency (0.6) (0.7) 0 (0.0) other pituitary hormone deficits 487 (62.2) 428 (62.2) 9 (62.1) 0.98 Pituitary surgery b 726 (92.8) 639 (93.0) 87 (91.6) 0.61 Radiotherapy c 390 (0.2) 372 (4.) 18 (18.9) <0.001 If radiotherapy, then postoperative radiotherapy 386 (99.0) 368 (98.9) 18 (100) 0.99 Radiotherapy dose, Gy (mean, SD) d 46.2 (.9) 46.3 (6.0) 46.0 (3.9) 0.82 Time between NFPA treatment and start GH-RT, years 3.6 (-1.6 to 46.0) 3.8 (-0.17 to 46.0) 1.7 (-1.6 to 19.9) <0.001 (median, range) e Onset of GHD, childhood onset (0.6) (0.7) 0 (0.0) 1.00 Smoking f 0.86 Yes 184 (28.0) 163 (28.2) 21 (26.9) Former 168 (2.6) 146 (2.3) 22 (28.2) No 304 (46.3) 269 (46.) 3 (44.9) Alcohol use g 246 (46.) 218 (47.1) 28 (42.4)
8 Table 1 (continued) All patients No tumor progression Tumor progression P-value a Medical history h Tumor progression 120 (1.6) 106 (1.6) 14 (1.4) 0.9 NFPA, nonfunctioning pituitary adenoma; IGHD, isolated growth hormone deficiency; ACTH, adrenocorticotropic hormone; TSH, thyrotrophin; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ADH, antidiuretic hormone; PRL, prolactin; Gy, gray; GH-RT, growth hormone replacement therapy; GHD, growth hormone deficiency Variables are presented as number (percentage) unless stated otherwise. a Continuous variables were tested with either the Student s t-test or the Mann-Whitney U-test. Categorical variables were examined with the Chi-square or Fisher s exact test. b-d Missing subjects: b n=1; c n=6; d n=97 e Time from surgery or primary radiotherapy for the nonfunctioning pituitary adenoma or first confirming of the nonfunctioning pituitary adenoma on pituitary imaging when no surgery or radiotherapy was initiated until start of growth hormone replacement therapy. f-h Missing subjects: f n=127; g n=24; h n=14 96
9 Tumor progression in NFPA patients using GH-RT Table 2 Baseline radiological nonfunctioning pituitary adenoma characteristics of all patients and of patients with and without tumor progression All patients No tumor progression Tumor progression P-value a Baseline scan available 96 (76.1) 18 (7.3) 78 (82.1) 0.14 Type of scan, MRI b 60 (94.8) 487 (94.9) 73 (93.6) 0.9 Residual tumor at baseline c 363 (62.9) 298 (9.7) 6 (83.3) <0.001 Tumor size, macroadenoma d 289 (83.3) 233 (82.0) 6 (88.9) 0.19 If macroadenoma: extrasellar extension e 223 (82.6) 181 (83.4) 42 (79.2) 0.47 Suprasellar extension f 147 (67.1) 119 (67.2) 28 (66.7) 0.94 Involvement optic chiasm g 44 (20.3) 36 (20.6) 8 (19.0) 0.83 Parasellar extension f 130 (9.4) 10 (9.0) 2 (61.0) 0.82 Infrasellar extension h 24 (10.8) 17 (9.4) 7 (16.7) 0.18 MRI, magnetic resonance imaging Variables are presented as number (percentage). a Variables were examined with the Chi-square or Fisher s exact test. b-h Missing subjects: b n=; c n=19; d n=16; e n=20; f n=4; g n=6; h n=1 Growth hormone replacement therapy The median follow-up time for the total study population was.2 ( ) years;.1 ( ) years, representing 3981 person-years of GH-RT, for patients without tumor progression and 6.0 ( ) years, being 4701 treatment-years, for patients with tumor progression (p = 0.10). The median GH dose did not differ between the two groups (0.28 [ ] vs [ ] mg per day). Tumor progression Tumor progression developed in 9 (12.1%) patients after a median follow-up of 2.2 ( ) years. Most patients (92.6%) had undergone NFPA treatment before the progression occurred; 69 (72.6%) had undergone pituitary surgery alone, whereas 19 (20%) had received surgery and postoperative radiotherapy. Median time between prior treatment and tumor progression was.1 ( ) years. After tumor progression, 17 (17.9%) patients were treated with surgery alone, 36 (37.9%) with radiotherapy alone, and 10 (10.%) with surgery and postoperative radiotherapy, whereas in 32 (33.7%) patients close monitoring was deemed adequate. In 20 (21.1%) patients, GH-RT was stopped because of the tumor progression, whereas in 16 (16.8%) patients it was temporarily discontinued for a median duration of 1.4 ( ) months. 97
10 Progression-free survival Follow-up time (years) Patients at risk Figure 1 Kaplan-Meier curve of the progression-free survival of the total study population Figure 2 Kaplan-Meier curve of the progression-free survival of patients who had and had not received prior radiotherapy Progression-free survival and comparison of subgroups The progression-free survival of the total study population is shown in figure 1. Of all patients, 399 (1.4%) had received radiotherapy as part of the prior tumor treatment (in six patients it was unknown whether they had received radiotherapy). Tumor progression occurred in 19 (4.8%) of these patients, whereas in the patients without prior radiotherapy tumor progression occurred in 76 (20.1%). Cox proportional hazard 98
11 Tumor progression in NFPA patients using GH-RT No residual tumor Residual tumor Progression-free survival Follow-up time (years) Patients at risk No residual tumor Residual tumor Figure 3 Kaplan-Meier curve of the progression-free survival of patients with and without residual tumor at baseline analysis demonstrated that patients who had received prior radiotherapy had a decreased risk of developing tumor progression compared with those who had not received prior radiotherapy, also after adjustment for age and gender (hazard ratio [HR] = 0.16, 9% confidence interval [CI], , p < 0.001). Age at NFPA diagnosis, extension of pituitary deficiency, surgery and history of tumor progression were not found to be relevant confounders. The progression-free survival of patients with and without prior radiotherapy is shown in figure 2. In 363 (62.6%) of the patients with baseline imaging data, there was evidence of residual adenoma at baseline (table 2). Tumor progression was observed in 6 (17.9%) of these patients, whereas in patients without residual tumor this was observed in 13 (6.1%) cases. Cox proportional hazard analysis in patients with available baseline imaging data showed that patients with residual tumor at baseline had an increased risk of developing tumor progression compared with patients without residual tumor, also after adjustment for age and gender (HR = 3.7, 9% CI, , p < 0.001). Of the other evaluated potentially confounding variables (age at NFPA diagnosis, extension of pituitary deficiency, surgery, radiotherapy and history of tumor progression), radiotherapy emerged as the only relevant confounder (HR after adjustment for age, gender and radiotherapy = 4., 9% CI, , p < 0.001). The progression-free survival of patients with and without residual tumor is shown in figure 3. Within the subgroup of patients with residual adenoma at baseline, nine (.4%) patients who had received prior radiotherapy developed tumor progression, 99
12 compared to 6 (28.9%) patients who had not received prior radiotherapy (p < 0.001). Within the group of patients without residual tumor at baseline, two (2.1%) patients with prior radiotherapy developed tumor progression vs. 11 (9.3%) patients without prior radiotherapy. Discussion GHD frequently occurs in patients with NFPAs, either as a consequence of the treatment of the tumor, the tumor itself, or a combined effect of both 2,7. GH-RT has shown positive effects on features associated with adult GHD However, it has been suggested GH-RT may increase the risk of tumor recurrence or growth, despite mostly reassuring data in literature so far 24. In the present observational study in a large cohort of NFPA patients using GH-RT, tumor progression developed in 12.1% of the patients after a median of 2.2 ( ) years after starting GH-RT in adulthood. Radiotherapy as part of prior NFPA treatment significantly decreased the risk of tumor progression. Residual tumor was associated with an increased risk of tumor progression. Several studies have investigated recurrence or regrowth of PAs after surgery and/or radiotherapy in patients not using GH-RT. In a series of 19 NFPA patients, tumor recurrence or regrowth occurred in 33.% after a median of 4.1 (1-20.7) years following surgery 28. In two other studies including NFPA patients who had undergone transsphenoidal surgery, recurrence rates were 21% and 32%, respectively 29,30. After pituitary radiotherapy, lower recurrences rates have been reported. Gittoes et al. found that only 4 of 63 (6%) postoperatively irradiated NFPA patients developed tumor progression, whereas 27 of 63 (43%) patients who were not postoperatively irradiated developed tumor progression 3. Likewise, in a cohort of 122 NFPA patients, tumor progression occurred in 4% and 7%, respectively, of patients with and without postoperative radiotherapy 4. In a series of 411 patients with various types of PAs who had all received radiotherapy, whether or not combined with surgery, only 2 (6%) patients developed tumor progression 6. The tumor progression rates in the entire cohort and in patients with or without prior radiotherapy of 12.1%, 4.8% and 20.1%, respectively, in the present study, appear to be similar to or lower than those reported by the abovementioned studies. This could indicate that GH-RT may not impose an increased risk of tumor progression in NFPA patients. However, several aspects that may widely vary between studies, such as treatment related factors (e.g. surgical technique, extent of surgery, radiotherapy), study population, tumor characteristics, and follow-up duration have to be taken into account when comparing different studies. 100
13 Tumor progression in NFPA patients using GH-RT So far only few studies in the literature have explored the possible effect of GH-RT on tumor progression in NFPA patients specifically 11,17,19,20. Buchfelder et al. compared operated NFPA patients who were either treated with GH-RT or not in a retrospective case-control study of matched pairs 20. Within a -year follow-up period, tumor progression occurred in 29.1% of the treatment group and in 21.8% of the control group (p = 0.2). Because data for this study were partly derived from the German KIMS database (Pfizer International Metabolic Database), treated patients were selected from multiple centers with differences in surgical expertise, whereas control patients were selected from one specialized neurosurgical center. Also, no adjustments were made for the proportion of patients in both groups, approximately 20%, who had received postoperative radiotherapy. Arnold et al. assessed the effect of GH-RT on tumor recurrence in 130 NFPA patients who were solely treated with surgery and followed up in a single center 19. Tumor progression occurred in 3% of 23 patients with GH-RT and in 36% of 107 patients without GH-RT. Further analysis revealed that GH-RT was not a significant predictor of progression after adjustment for several confounders. In another case-control study in NFPA patients using GH-RT (n = 121) or not (n = 114), the progression-free survival rates were similar in both groups 17. During an observation period of approximately 10 years, tumor progression was found in 26% of the GH-treated patients and in 32% of the non-gh-treated patients. Although the nonrandomized nature of these studies could have led to bias with regard to the choice for GH-RT, for instance, because patients with larger (residual) tumors may have been less likely to receive GH-RT and the sample sizes were limited, all these studies suggest that GH-RT does not increase tumor progression risk. The observed tumor progression rates in the present study seem to be comparable with or lower than those reported in literature. The rate of 12.1% in our entire study population was lower than those in the treatment and control groups of the three aforementioned studies 17,19,20. This may be due to differences in sample size, whether radiotherapy was administered, or follow-up time. Nevertheless, the results of the present study support data in literature that GH-RT, aiming at restoring physiological IGF-1 concentrations, does not appear to have a negative impact on tumor progression in patients with a NFPA. Radiotherapy significantly decreased the risk of tumor progression in the present study. This association was not influenced by potentially confounding variables. Similar findings have been reported by others 3,4,6,17. Although radiotherapy has positive effects on tumor control, concerns have been raised about long-term side effects such as hypopituitarism and increased risks of cerebrovascular events (CVEs) or secondary intracranial tumors 2,, It has been postulated that GH-RT may enhance this risk of secondary tumors because of the potential mitogenic effects of GH and IGF-1 and 101
14 reports of increased risk of secondary tumors in childhood cancer survivors or children treated with GH-RT 13,3-37. However, in other studies, no increased risk of secondary neoplasms in patients receiving GH-RT after central nervous system irradiation nor an association between IGF-1 concentration and the occurrence of malignancies in GHtreated adults were observed 18,38. These findings are line with previous reports from our registry. In one study, mortality due to malignancies was not elevated in adults receiving GH-RT compared to the background population 27. In another study, the occurrence of secondary intracranial tumors did not differ between irradiated and nonirradiated NFPA patients (1.1% vs. 0.6%), but the risk of CVE was increased in irradiated men 31. Overall, as discussed in a recent review, fatal and nonfatal malignancies do not appear to be more prevalent in GH-treated adults compared to the general population, and also not in previously irradiated patients 11,18. Nevertheless, potential side effects of pituitary irradiation should be carefully balanced against benefits. The presence of residual tumor at baseline significantly increased tumor progression risk in the present study, also after adjustment for potential confounders. This has also been observed by others 17,20,21. Olsson et al. found that tumor progression developed in 37% and 10% of patients using GH-RT with and without residual tumor, respectively, compared to 17.9% and 6.1% in the present study 17. They suggested that, because the rates in their treatment group, including patients with residual tumor, were comparable with those in the control group and those in literature, GH-RT may also be safely administered in patients with residual tumor. This is in line with the findings in the present study. For instance, in the subgroup of our patients with residual tumor who had not received radiotherapy, 28.9% developed tumor progression, which is comparable with reported ranges, varying between 21% and 7%, in surgically treated, but nonirradiated, NFPA patients not using GH-RT 3,4,19, In addition, Arnold et al. showed that after adjustment for several confounders, including type of tumor removal (partial or complete), GH-RT was not a predictor of recurrence 19. These combined data indicate that GH-RT may also be initiated in the presence of residual NFPA, although long-term surveillance is recommended. The present study has both strengths and limitations. The large size of the study population, including only patients with a NFPA and excluding other types of tumors, is one of the major strengths. Due to this large number, comparisons between different subgroups could be made. Furthermore, potentially confounding effects of several factors were evaluated. The follow-up duration was relatively long and similar between patients with and without tumor progression. However, one could argue that the follow-up period might not have been long enough to detect tumor growth in the usually slow-growing NFPAs. A limitation of our study is the lack of a control group of untreated GHD patients with a NFPA. However, our findings were compared 102
15 Tumor progression in NFPA patients using GH-RT with those in literature, thereby taking into account the difficulties of such comparisons. The nonrandomized and retrospective design, inherent to the observational nature of the database, presents another limitation. Unfortunately, performing a prospective randomized study in NFPA patients does not seem feasible due to practical and ethical constraints. In summary, in this observational study in a large number of NFPA patients using GH-RT, the development of tumor progression was investigated. The findings in this study in combination with those reported in literature, thereby taking into account the presented limitations, indicate that GH-RT does not seem to increase the risk of tumor progression. Although more robust conclusions may only be generated by large randomized prospective studies with long-term follow-up, evidence so far seems reassuring. Data suggest that GH-RT, with regard to tumor progression, may be safely administered to GHD patients with a NFPA. Acknowledgements Establishing the Dutch National Registry of Growth Hormone Treatment in Adults was financed by the Health Care Insurance Board. We are very grateful to all colleagues at the Internal Medicine and Endocrine Departments of all participating Dutch hospitals for their collaboration. 103
16 References 1. Raappana A, Koivukangas J, Ebeling T et al. Incidence of pituitary adenomas in Northern Finland in J Clin Endocrinol Metab 2010; 9(9): Dekkers OM, Pereira AM, Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 2008; 93(10): Gittoes NJ, Bates AS, Tse W et al. Radiotherapy for non-function pituitary tumours. Clin Endocrinol (Oxf) 1998; 48(3): van den Bergh AC, van den Berg G, Schoorl MA et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 2007; 67(3): Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96(7): Brada M, Rajan B, Traish D et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993; 38(6): Corneli G, Baldelli R, Di Somma C et al. Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. Growth Horm IGF Res 2003; 13(2-3): de Boer H, Blok GJ, van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 199; 16(1): Jorgensen AP, Fougner KJ, Ueland T et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm IGF Res Gibney J, Wallace JD, Spinks T et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999; 84(8): van Bunderen CC, van Varsseveld NC, Erfurth EM et al. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol (Oxf) 2014; 81(1): Khandwala HM, McCutcheon IE, Flyvbjerg A et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21(3): Ng ST, Zhou J, Adesanya OO et al. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 1997; 3(10): Dworakowska D, Gueorguiev M, Kelly P et al. Repeated colonoscopic screening of patients with acromegaly: 1-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol 2010; 163(1): Renehan AG, Zwahlen M, Minder C et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363(9418): Hartman ML, Xu R, Crowe BJ et al. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab 2013; 98(3): Olsson DS, Buchfelder M, Schlaffer S et al. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Eur J Endocrinol 2009; 161(): Mackenzie S, Craven T, Gattamaneni HR et al. Long-Term Safety of Growth Hormone Replacement after CNS Irradiation. J Clin Endocrinol Metab
17 Tumor progression in NFPA patients using GH-RT 19. Arnold JR, Arnold DF, Marland A et al. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol (Oxf) 2009; 70(3): Buchfelder M, Kann PH, Wuster C et al. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur J Endocrinol 2007; 17(2): Hatrick AG, Boghalo P, Bingham JB et al. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol 2002; 146(6): Abs R, Bengtsson BA, Hernberg-Stahl E et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 1999; 0(6): Frajese G, Drake WM, Loureiro RA et al. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab 2001; 86(11): Molitch ME, Clemmons DR, Malozowski S et al. Evaluation and treatment of adult growth hormone deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(6): Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998; 83(2): van Nieuwpoort IC, van Bunderen CC, Arwert LI et al. Dutch National Registry of GH Treatment in Adults: patient characteristics and diagnostic test procedures. Eur J Endocrinol 2011; 164(4): van Bunderen CC, van Nieuwpoort IC, Arwert LI et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab 2011; 96(10): O Sullivan EP, Woods C, Glynn N et al. The natural history of surgically treated but radiotherapynaive nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 2009; 71(): Turner HE, Stratton IM, Byrne JV et al. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clin Endocrinol (Oxf) 1999; 1(3): Comtois R, Beauregard H, Somma M et al. The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 1991; 68(4): van Varsseveld NC, van Bunderen CC, Ubachs DH et al. Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the dutch national registry of growth hormone treatment in adults. J Clin Endocrinol Metab 201; 100(3): Tsang RW, Laperriere NJ, Simpson WJ et al. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 1993; 72(7): Brada M, Burchell L, Ashley S et al. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys 1999; 4(3): Minniti G, Traish D, Ashley S et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 200; 90(2): Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4(7): Swerdlow AJ, Higgins CD, Adlard P et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 199-8: a cohort study. Lancet 2002; 360(9329):
18 37. Ergun-Longmire B, Mertens AC, Mitby P et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91(9): Popovic V, Mattsson AF, Gaillard RC et al. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 2010; 9(9):
Somatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234)
Somatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland. In patients
More informationProlactin-Secreting Pituitary Adenomas (Prolactinomas) The Diagnostic Pathway (11-2K-234)
Prolactin-Secreting Pituitary Adenomas (Prolactinomas) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland.
More information3. BACKGROUND AND RATIONALE
CHILDHOOD CANCER SURVIVOR STUDY Revised Analysis Concept Proposal 10-17 October 12, 2011 1. STUDY TITLE: Growth Hormone Exposure as a risk factor for the development of Subsequent Central Nervous System
More informationProcess / Evidence Class. Clinical Assessment / III
Table 2: Endocrine Author Cozzi et al (2009) 1 Study Design: Prospectively followed case series. Fourteen patients had pre-op hypocortisolism. Patient Population: Seventy-two adult patients who underwent
More informationComparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy
European Journal of Endocrinology (2009) 161 663 669 ISSN 0804-4643 CLINICAL STUDY Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH
More informationLong-term results of gamma knife surgery for growth hormone producing pituitary adenoma: is the disease difficult to cure?
J Neurosurg (Suppl) 102:119 123, 2005 Long-term results of gamma knife surgery for growth hormone producing pituitary adenoma: is the disease difficult to cure? TATSUYA KOBAYASHI, M.D., PH.D., YOSHIMASA
More informationThe clinical characteristics of three subgroups of non-functioning pituitary adenomas
World Journal of Neuroscience, 2014, 4, 75-84 http://dx.doi.org/10.4236/wjns.2014.41009 Published Online February 2014 (http://www.scirp.org/journal/wjns/) WJNS The clinical characteristics of three subgroups
More informationRadiotherapy approaches to pituitary tumors
Disclosures No relevant disclosures Radiotherapy approaches to pituitary tumors Pituitary Disorders: Advances in Diagnosis and Management Steve Braunstein, MD, PhD UCSF Department of Radiation Oncology
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/33195 holds various files of this Leiden University dissertation. Author: Appelman-Dijkstra, Natasha Mireille Title: Long-term consequences of growth hormone
More informationTABLES. Table 1: Imaging. Congress of Neurological Surgeons Author (Year) Description of Study Classification Process / Evidence Class
TABLES Table 1: Imaging Kremer et al (2002) 2 Study Design: Prospective followed case series. Patient Population: Fifty adult patients with NFPA Study Description: Patients underwent MRI before surgery,
More informationIndividual Risk Factors of the Metabolic Syndrome in Adult Patients with Growth Hormone Deficiency A Cross-sectional Case-control Study
39 Individual Risk Factors of the Metabolic Syndrome in Adult Patients with Growth Hormone Deficiency A Cross-sectional Case-control Study Authors I. Uzunova 1, G. Kirilov 1, S. Zacharieva 1, A. Shinkov
More informationPostoperative surveillance of clinically nonfunctioning. pituitary macroadenomas: markers of tumour quiescence and regrowth
Clinical Endocrinology (2003) 58, 763 769 Postoperative surveillance of clinically nonfunctioning Blackwell Publishing Ltd. pituitary macroadenomas: markers of tumour quiescence and regrowth Y. Greenman*,
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Norditropin (somatropin)
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Zomacton (somatropin) Must
More informationClinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION
Clinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION Date of First Issue 01/04/2015 Approved 28/01/2016 Current Issue Date 28/01/2016 Review
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 5, 2014 Growth Hormone Adult
More information2 Immediate postoperative
2 Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy Alfons
More informationAbstract. Introduction
Clinical Features and Outcome of Surgery in 30 Patients with Acromegaly A. Chandna, N. Islam, A. Jabbar, L. Zuberi, N. Haque Endocrinology Section, Department of Medicine, Aga Khan University Hospital,
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT
1. Medical Condition GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT Growth Hormone Deficiency and other indications for growth hormone therapy (adult). 2. Diagnosis A.
More informationHypothalamus & Pituitary Gland
Hypothalamus & Pituitary Gland Hypothalamus and Pituitary Gland The hypothalamus and pituitary gland form a unit that exerts control over the function of several endocrine glands (thyroid, adrenals, and
More informationHigh and Low GH: an update of diagnosis and management of GH disorders
High and Low GH: an update of diagnosis and management of GH disorders Georgia Chapter-AACE 2017 Laurence Katznelson, MD Professor of Medicine and Neurosurgery Associate Dean of Graduate Medical Education
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationClinical Concerns about Recurrence of Non-Functioning Pituitary Adenoma
ORIGINAL ARTICLE Brain Tumor Res Treat 2016;4(1):1-7 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.1.1 Clinical Concerns about Recurrence of Non-Functioning Pituitary Adenoma
More informationEndocrinological Outcome Among Treated Craniopharyngioma Patients
Endocrinological Outcome Among Treated Craniopharyngioma Patients Afaf Al Sagheir, MD Head & Consultant, Section of Endocrinology/Diabetes Department of Pediatrics KFSH&RC Introduction Craniopharyngiomas
More informationPituitary Tumors and Incidentalomas. Bijan Ahrari, MD, FACE, ECNU Palm Medical Group
Pituitary Tumors and Incidentalomas Bijan Ahrari, MD, FACE, ECNU Palm Medical Group Background Pituitary incidentaloma: a previously unsuspected pituitary lesion that is discovered on an imaging study
More informationAcromegaly: Management of the Patient Who Has Failed Surgery
Acromegaly: Management of the Patient Who Has Failed Surgery Minnesota/Midwest Chapter of the American Association of Clinical Endocrinologists 8 th Annual Meeting October 14, 2017 Mark E. Molitch, M.D.
More informationPITUITARY: JUST THE BASICS PART 2 THE PATIENT
PITUITARY: JUST THE BASICS PART 2 THE PATIENT DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none Steps taken to review and
More informationThe development of a manageable medical
Developing a Rational Approach for the Use of Growth Hormone in npediatric Patients David Cook, MD; and Gary Owens, MD The development of a manageable medical policy that ensures appropriate use of recombinant
More informationImaging pituitary gland tumors
November 2005 Imaging pituitary gland tumors Neel Varshney,, Harvard Medical School Year IV Two categories of presenting signs of a pituitary mass Functional tumors present with symptoms due to excess
More informationENDOCRINE OUTCOMES OF TRANS-SPHENOIDAL SURGERY FOR PITUITARY APOPLEXY VERSUS ELECTIVE SURGERY FOR PITUITARY ADENOMA
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationRadioterapia degli adenomi ipofisari
Radioterapia degli adenomi ipofisari G Minniti Radiation Oncology, Sant Andrea Hospital, University of Rome Sapienza, and IRCCS Neuromed, Pozzilli (IS) Roma 6-9 Novembre 14 ! Outline " Radiation techniques
More informationRadiotherapy in the management of optic pathway gliomas
Turkish Journal of Cancer Vol.30/ No.1/2000 Radiotherapy in the management of optic pathway gliomas FARUK ZORLU, FERAH YILDIZ, MURAT GÜRKAYNAK, FADIL AKYOL, İ. LALE ATAHAN Department of Radiation Oncology,
More informationPituitary, Parathyroid Pheochromocytomas & Paragangliomas: The 4 Ps of NETs
Pituitary, Parathyroid Pheochromocytomas & Paragangliomas: The 4 Ps of NETs Shereen Ezzat, MD, FRCP(C), FACP Professor Of Medicine & Oncology Head, Endocrine Oncology Princess Margaret Hospital/University
More informationJMSCR Vol 05 Issue 01 Page January 2017
MEN1, AIP, PRKAR1A and CDKN1B are familial pituitary syndromes found to be associated with four different genes. Pituitary gland is situated in hypophyseal fossa which is bounded supero-laterally by dural
More informationPituitary Macroadenoma with Superior Orbital Fissure Syndrome
1 CASE REPORT OPEN ACCESS Pituitary Macroadenoma with Superior Orbital Fissure Syndrome Tapan Nagpal, Ankit Singhania ABSTRACT Introduction: Pituitary adenomas are benign tumours which arise within the
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationGrowth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years
European Journal of Endocrinology (2002) 147 59 63 ISSN 0804-4643 CLINICAL STUDY Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years C W le Roux,
More informationClinical Commissioning Policy Proposition: Stereotactic radiosurgery/ radiotherapy for the treatment of pituitary adenomas [Adults]
Clinical Commissioning Policy Proposition: Stereotactic radiosurgery/ radiotherapy for the treatment of pituitary adenomas [Adults] Reference: NHS England 1603 First published: TBC Prepared by NHS England
More informationSee the latest estimates for new cases of pituitary tumors in the US and what research is currently being done.
About Pituitary Tumors Overview and Types If you have been diagnosed with a pituitary tumor or worried about it, you likely have a lot of questions. Learning some basics is a good place to start. What
More informationEvidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.
Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationEndocrine Glands. Endocrine glands
ENDOCRINOLOGY Endocrine Glands Endocrine glands Produce substances called hormones. Ductless glands, i.e., they release hormones directly into the bloodstream Hormones only act at their target tissue where
More information33 year old male with a history of resected craniopharyngioma (12 years ago) presents after a seizure. Jess Hwang 9/27/12
33 year old male with a history of resected craniopharyngioma (12 years ago) presents after a seizure Jess Hwang 9/27/12 Craniopharyngioma history In 2000, at age 22, he presented with headache and blurry
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationRESEARCH ARTICLE. Abstract. Introduction. Materials and Methods
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.13.5279 Outcomes after Linac Based SRS/FSRT for Pituitary Adenomas RESEARCH ARTICLE Outcomes for Pituitary Adenoma Patients Treated with Linac- Based Stereotactic
More informationPROCARE FINAL FEEDBACK
1 PROCARE FINAL FEEDBACK General report 2006-2014 Version 2.1 08/12/2015 PROCARE indicators 2006-2014... 3 Demographic Data... 3 Diagnosis and staging... 4 Time to first treatment... 6 Neoadjuvant treatment...
More informationA Boy with Optic Glioma
Clin Pediatr Endocrinol 1994;3(Suppl 4): 169-173 Copyright(C)1994 by The Japanese Society for Pediatric Endocrinology Taisuke Okada, Sumitaka Dohno, Yousei Shimasaki, Takashi Tomoda, Makiko Koga, Kumiko
More informationClinical Commissioning Policy: Stereotactic radiosurgery/ radiotherapy for the treatment of pituitary adenomas (all ages)
Clinical Commissioning Policy: Stereotactic radiosurgery/ radiotherapy for the treatment of pituitary adenomas (all ages) NHS England Reference: 170044P 1 NHS England INFORMATION READER BOX Directorate
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationImaging The Turkish Saddle. Russell Goodman, HMS III Dr. Gillian Lieberman
Imaging The Turkish Saddle Russell Goodman, HMS III Dr. Gillian Lieberman Learning Objectives Review the anatomy of the sellar region Discuss the differential diagnosis of sellar masses Discuss typical
More information1. Study Title. Exercise and Late Mortality in 5-Year Survivors of Childhood Cancer: a Report from the Childhood Cancer Survivor Study.
CCSS Analysis Concept Proposal Exercise, Mortality, & Childhood Cancer 1 1. Study Title. Exercise and Late Mortality in 5-Year Survivors of Childhood Cancer: a Report from the Childhood Cancer Survivor
More informationDepartment of Neurosurgery and The California Center for Pituitary Disorders, University of California, San Francisco, California
clinical article J Neurosurg 124:589 595, 2016 Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis
More informationManagement of incidental pituitary microadenomas: a cost-effectiveness analysis King J T, Justice A C, Aron D C
Management of incidental pituitary microadenomas: a cost-effectiveness analysis King J T, Justice A C, Aron D C Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationChapter 13 worksheet
Name: Chapter 13 worksheet The Endocrine System Please label the: hypothalamus pineal gland pituitary gland thyroid gland parathyroid gland thymus heart stomach liver adrenal glands kidneys pancreas small
More informationIncreased risk of cancer with anti-diabetes drugs? : pros
24 th Spring Congress of Korean Diabetes Association Increased risk of cancer with anti-diabetes drugs? : pros Nan Hee Kim, MD, Ph.D. Professor Korea University Medical School Contents Diabetes and cancer
More informationImpact of Gamma Knife Radiosurgery on the neurosurgical management of skull-base lesions: The Combined Approach
Radiosurgery as part of the neurosurgical armamentarium: Educational Symposium November 24 th 2011 Impact of Gamma Knife Radiosurgery on the neurosurgical management of skull-base lesions: The Combined
More informationCertain types of tumors, in the CNS and elsewhere,
clinical article J Neurosurg 122:798 802, 2015 Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly Lucia Schwyzer, MD, Robert M. Starke, MD, John
More informationPITUITARY ADENOMAS. Effective Date: August, 2012
CLINICAL PRACTICE GUIDELINE CNS-00 PITUITARY ADENOMAS Effective Date: August, 2012 The recommendations contained in this guideline are a consensus of the Alberta Provincial CNS Tumour Team synthesis of
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 8, 2017 Growth Hormone Adult
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationThis slide kit covers more complex thyroid eye disease.
An imbalance in the normal level of thyroid hormone in the body can cause thyroid eye disease. If you wish to explore information on the basics of thyroid eye diseases, please first see: https://www.excemed.org/manage-thyroid-online/resources/thyroid-eyedisease
More informationCraniopharyngioma. Michael Gottschalk, MD,PhD University of California San Diego Rady Children s Hospital
Craniopharyngioma Michael Gottschalk, MD,PhD University of California San Diego Rady Children s Hospital Objectives Incidence Clinical Presentation Treatment Options Perioperative concerns Long-term endocrine
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
Douglas et al. BMC Cancer 2012, 12:425 RESEARCH ARTICLE Open Access A new score predicting the survival of patients with spinal cord compression from myeloma Sarah Douglas 1, Steven E Schild 2 and Dirk
More informationImpact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis?
Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis? Thomas André Ankill Kämpe 30.05.2016 MED 3950,-5 year thesis Profesjonsstudiet i medisin
More informationTABLES. Imaging Modalities Evidence Tables Table 1 Computed Tomography (CT) Imaging. Conclusions. Author (Year) Classification Process/Evid ence Class
TABLES Imaging Modalities Evidence Tables Table 1 Computed Tomography (CT) Imaging Author Clark (1986) 9 Reformatted sagittal images in the differential diagnosis meningiomas and adenomas with suprasellar
More informationGrowth Hormone!gents. WA.PHAR.50 Growth Hormone Agents
Growth Hormone!gents WA.PHAR.50 Growth Hormone Agents Background: Human growth hormone, also known as somatotropin, is produced in the anterior lobe of the pituitary gland. This hormone plays an important
More informationGH Replacement Therapy in Growth Hormone Deficient Adults
GH Replacement Therapy in Growth Hormone Deficient Adults Sequence of hormone loss in hypopituitarism depending on location of a benign tumor Besser GM, Cudworth AG, eds. Clinical endocrinology: an illustrated
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationPathology of pituitary gland. By: Shifaa Qa qa
Pathology of pituitary gland By: Shifaa Qa qa Sella turcica Adenohypophysis (80%): - epithelial cells - acidophil, basophil, chromophobe - Somatotrophs, Mammosomatotrophs, Corticotrophs, Thyrotrophs, Gonadotrophs
More informationUW MEDICINE PATIENT EDUCATION. Acromegaly Symptoms and treatments. What is acromegaly? DRAFT. What are the symptoms? How is it diagnosed?
UW MEDICINE PATIENT EDUCATION Acromegaly Symptoms and treatments This handout explains a health condition called acromegaly. It describes tests that are used to diagnose the condition and gives basic instructions
More informationA survey of pituitary incidentaloma in Japan
European Journal of Endocrinology (2003) 149 123 127 ISSN 0804-4643 CLINICAL STUDY A survey of pituitary incidentaloma in Japan Naoko Sanno, Ken ichi Oyama, Shigeyuki Tahara, Akira Teramoto and Yuzuru
More informationThe Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors
The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors Avner Hershlag MD Professor and Chief Center for Human Reproduction North Shore LIJ Hofsra university School of Medicine
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationLong- term outcome for patients with craniopharyngiomas
1 Long- term outcome for patients with craniopharyngiomas Eric Tande Håland Tutor: Jon Berg- Johnsen Department of Neurosurgery Oslo University Hospital Faculty of Medicine UNIVERSITY OF OSLO 2017 2 Contents
More information(3) Pituitary tumours
Hypopituitarism Diabetes Insipidus Pituitary tumours (2) Dr T Kemp - Endocrinology and Metabolism Unit - Steve Biko Academic Hospital (3) Pituitary tumours Pituitary microadenoma - intrasellar adenoma
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationSurgical therapeutic strategy for giant pituitary adenomas.
Biomedical Research 2017; 28 (19): 8284-8288 ISSN 0970-938X www.biomedres.info Surgical therapeutic strategy for giant pituitary adenomas. Han-Shun Deng, Zhi-Quan Ding, Sheng-fan Zhang, Zhi-Qiang Fa, Qing-Hua
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 20, 2018 Growth Hormone
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationCATEGORY Endocrine System Review. Provide labels for the following diagram CHAPTER 13 BLM
CHAPTER 13 BLM 13.1.1 CATEGORY Endocrine System Review Provide labels for the following diagram. 1. 6. 2. 7. 3. 8. 4. 9. 5. 10. CHAPTER 13 BLM 13.1.2 OVERHEAD Glands and Their Secretions Endocrine gland
More informationLong term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas
Pituitary (2010) 13:223 229 DOI 10.1007/s11102-010-0221-z Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas Edward F. Chang Michael E. Sughrue
More informationACROMEGALY OCCURRING IN A PATIENT WITH A PITUITARY ADENOMA, LYMPHOCYTIC HYPOPHYSITIS, AND A RATHKE CLEFT CYST
Case Report ACROMEGALY OCCURRING IN A PATIENT WITH A PITUITARY ADENOMA, LYMPHOCYTIC HYPOPHYSITIS, AND A RATHKE CLEFT CYST Anupa Sharma, DO 1 ; Eric K.Richfield, MD, PhD 2 ; Sara E. Lubitz, MD 1 ABSTRACT
More informationGrowth Hormone: Review of the Evidence
Drug Use Research & Management Program DHS Division of Medical Assistance Programs, 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Growth Hormone: Review of the Evidence
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationEpidemiology And Treatment Of Cerebral Aneurysms At An Australian Tertiary Level Hospital
ISPUB.COM The Internet Journal of Neurosurgery Volume 9 Number 2 Epidemiology And Treatment Of Cerebral Aneurysms At An Australian Tertiary Level Hospital A Granger, R Laherty Citation A Granger, R Laherty.
More informationOriginal Article. Abstract. Introduction. Thinesh Kumran 1,2, Saffari Haspani 1,2, Jafri Malin Abdullah 1,4, Azmi Alias 1,2, Fan Rui Ven 3
Original Article Factors Influencing Disconnection Hyperprolactinemia and Reversal of Serum Prolactin after Pituitary Surgery in a Non-Functioning Pituitary Macroadenoma Thinesh Kumran 1,2, Saffari Haspani
More informationAssessment of pituitary function in patients with nasopharyngeal carcinoma: The effect of radiotherapy
Available online at www.medicinescience.org ORIGINAL RESEARCH Medicine Science International Medical Journal Medicine Science 2019; ( ): Assessment of pituitary function in patients with nasopharyngeal
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationJOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
This is an author produced version of an article that appears in: JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM The internet address for this paper is: https://publications.icr.ac.uk/2224/ Published
More informationRobert Wadlow and his father
Robert Wadlow and his father 1 Robert Wadlow Wadlow reached 8 ft 11.1 in (2.72 m) in height and weighed 485 lb (220 kg) at his death at age 22. Born in Illinois. His great size and his continued growth
More informationIntroduction to Endocrinology. Hypothalamic and Pituitary diseases Prolactinoma + Acromegaly
Introduction to Endocrinology. Hypothalamic and Pituitary diseases Prolactinoma + Acromegaly Dr. Peter Igaz MD PhD DSc 2nd Department of Medicine Semmelweis University Fields of Endocrinology Diseases
More informationBIOM2010 (till mid sem) Endocrinology. e.g. anterior pituitary gland, thyroid, adrenal. Pineal Heart GI Female
BIOM2010 (till mid sem) Endocrinology Endocrine system Endocrine gland : a that acts by directly into the which then to other parts of the body to act on (cells, tissues, organs) : found at e.g. anterior
More information